Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms Clinical Trial

Official title:

A Phase 2, Multicenter, International, Single Arm Study To Assess The Safety And Efficacy Of Single Agent Cc-486 (Oral Azacitidine) In Previously Treated Subjects With Locally Advanced Or Metastatic Nasopharyngeal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02269943
• Other study ID #: CC-486-NPC-001
• Secondary ID: 2014-001745-25
• Status: Completed
• Phase: Phase 2
• Start date: February 13, 2015
• Est. completion date: April 20, 2017

Study information

• Verified date: November 2018
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including platinum-based chemotherapy. Participants will be enrolled according to a Simon two-stage design; if the predefined activity is met (>4 responses [complete response; partial response {CR/PR}] out of the first 17 evaluable participants based on independent radiological assessment), then the study will continue to enroll an additional 34 participants. If 4 or less responses out of 17 are observed, then the study enrollment will be stopped.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: April 20, 2017
• Est. primary completion date: April 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = or > 18 years Histological or cytological diagnosis of undifferentiated or poorly differentiated nasopharyngeal carcinoma that is locally advanced or metastatic.

• Disease progression either clinically or radiographically after 1-2 previous regimens.

• Patient has received a platinum containing regimen. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Radiographically-documented measureable disease.

• Adequate organ and bone marrow functions.

• Willingness to follow pregnancy precautions.

Exclusion Criteria:

• History of, or current brain metastasis. Any other malignancy within 5 years prior to randomization with the exception of adequately treated in situ carcinoma of the cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed 6 months prior to enrollment), in situ squamous cell carcinoma of the breast, or incidental prostate cancer.

• Previous treatment with azacitidine (any formulation), decitabine, any other hypomethylating agent.

• History of gastrointestinal disorder or defect. Impaired ability to swallow oral medication. Persistent diarrhea or malabsorption.

• Active cardiac disease and human immunodeficiency virus (HIV) infection

• Active bleeding; pathological condition that carries a high risk of bleeding; risk of pseudoaneurysm of the internal carotid artery and carotid blowout syndrome.

• Major surgery within 14 days prior to starting Investigational Product or has not recovered from major side effects.

• Another investigational therapy within 28 days or 5 half lives of randomization/enrollment, whichever is shorter.

• Patient has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.

• Radiotherapy < or = 4 weeks or limited field radiation for palliation < or = 2 weeks prior to starting with the investigational product.

• Pregnancy/Breast feeding

• Any condition that places the patient at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.

Related Conditions & MeSH terms

• Carcinoma
• Nasopharyngeal Neoplasms

Intervention

Drug:
• CC-486

Locations

Country	Name	City	State
Canada	McGill University	Montreal	Quebec
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
France	Institut Hospitalier Franco-Britannique	Levallois-Perret
France	Institut Curie	Paris
France	Institut Gustave Roussy	Villejuif Cedex
Greece	University General Hospital of Heraklion	Heraklion
Greece	Thermi Clinic	Thessaloniki
Italy	Istituto Nazionale Dei Tumori	Milano
Singapore	Johns Hopkins Singapore International Medical Centre	Singapore
Singapore	National Cancer Center	Singapore
Singapore	Singapore Oncology Consultants	Singapore
Spain	Instituto Catalan de Oncologia-Hospital Duran	Barcelona
Spain	Hospital Universitario Madrid Sanchinarro	Madrid
Spain	Hospital Universitario de Salamanca	Salamanca
Taiwan	Chang Gung Medical Foundation, Kaohsiung Memorial Hospital	Niao-Sung Hsiang Kaohsiung County
Taiwan	China Medical University Hospital	Taichung
Taiwan	Taichung Veterans General Hospital	Taichung
Tunisia	Hopital Abderrahman Mami de Pneumo-Phtisiologie de l'Ariana	Ariana
Tunisia	Institut Salah Azaiez	Bab Saadoun
Tunisia	Hospital Habib Bourguiba	Sfax
United States	Winship Cancer Institute of Emory University	Atlanta	Georgia
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	University of Chicago	Chicago	Illinois
United States	Columbia Comprehensive Cancer Care Clinic	Jefferson City	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Countries where clinical trial is conducted

United States,  Canada,  France,  Greece,  Italy,  Singapore,  Spain,  Taiwan,  Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent Radiology Assessment (IRA)	Overall response rate was defined as the combined incidence of Complete Response (CR) or Partial Response (PR), confirmed no less than 4 weeks after the criteria for response were first met, based on independent radiology assessment according to RECIST 1.1 criteria.; Complete response was defined as the disappearance of all target lesions and non-target lesions; Partial response is at least a 30% decrease from baseline in the sum of diameters of target lesions with no progression of non-target lesions and no new lesions or disappearance of target lesions with persistence of one or more non-target lesions from baseline.	Tumor response was assessed every (Q) 6 weeks for the first 3 evaluations then Q 9 weeks until disease progression as of the cut-off date of 08 August 2017; the median duration of treatment was 257 days for the 200 mg dose and 114.5 days for 300 mg dose
Primary	Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on an Independent Radiology Assessment According to RECIST 1.1 Criteria	PFS was defined as the time from the date of start of the study treatment to the date of disease progression or death (any cause) on or prior to the data cut-off date for the statistical analysis, whichever occurred earlier, based on an independent radiology assessment of response using RECIST v1.1 criteria. Progressive disease was defined as at least a 20% increase in the sum of diameters of target or non-target lesions from nadir or appearance of a new lesion.	From Day 1 of documented disease progression; up to data cut off date of 08 August 2017; median follow-up time for censored participants was 12.3 months
Secondary	Kaplan Meier Estimate of Overall Survival	Overall survival was the time from the first dose of study drug to patient death from any cause. Participants who did not die were censored at the last known time the patient was alive date or the clinical data cutoff date, whichever was earlier.	From Day 1 of study treatment to the first date of progressive disease or death; up to data cut-off date of 08 August 2017; overall median follow-up time for censored participants was 20.4 months
Secondary	Percentage of Participants With Stable Disease for = 16 Weeks From the Date of the First Treatment, or CR or PR According to RECIST 1.1 Criteria and Based on an Independent Radiology Assessment	Disease Control Rate (DCR) was defined as the percentage of participants with a CR, PR, confirmed = 4 weeks after the criteria for response were first met, or stable disease for = 16 weeks from the first treatment, based on independent radiology assessment using RECIST 1.1 criteria. A complete response was defined as the disappearance of all target lesions and non-target lesions; a partial response is at least a 30% decrease from baseline in the sum of diameters of target lesions with no progression of non-target lesions and no new lesions or disappearance of target lesions with persistence of one or more non-target lesions from baseline. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease	Tumor response was assessed every 6 weeks for the first 3 evaluations then every 9 weeks until disease progression. As of the cut-off date of 08 August 2017 the median duration of treatment was 257 days for the 200 mg dose and 114.5 days for 300 mg dose
Secondary	Number of Participants With Treatment Emergent Adverse Events	Treatment-emergent adverse events (TEAEs) were defined as any adverse event (AE) or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the investigational product (IP) through 28 days after the last dose of IP. In addition, any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and based on the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death.	From date of first dose of study treatment to 28 days after last dose of study treatment; up to final data cut-off date of 08 August 2017; median treatment duration was 257 days for CC-486 200 mg and 114.5 days for CC-486 300 mg
Secondary	Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration Of CC-486 (AUC-t)	Area under the plasma concentration-time curve from Time 0 to the time of the last quantifiable concentration, calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.	Blood samples for oral azacitidine PK assessment were collected prior to each dose (pre-dose) and over the 8-hour period following each dose (0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose or similar schedule).
Secondary	Area Under the Plasma Concentration -Time Curve From 0 Extrapolated to Infinity (AUC-inf, AUC0-8) Of CC-486	Area under the plasma concentration-time curve from Time 0 extrapolated to infinity, calculated as [AUCt + Ct/ ?z]. Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable ?z. If AUC %Extrap was =25%, AUC inf was not reported.	Blood samples for oral azacitidine PK assessment were collected prior to each dose (pre-dose) and over the 8-hour period following each dose (0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose or similar schedule).
Secondary	Maximum Observed Concentration (Cmax) Of CC-486	Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.	Blood samples for oral azacitidine PK assessment were collected prior to each dose (pre-dose) and over the 8-hour period following each dose (0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose or similar schedule).
Secondary	Time to Reach Maximum Concentration (Tmax) Of CC-486	Time to Cmax, obtained directly from the observed concentration versus time data.	Blood samples for oral azacitidine PK assessment were collected prior to each dose (pre-dose) and over the 8-hour period following each dose (0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose or similar schedule).
Secondary	Terminal Half-Life (t1/2) of CC-486	Terminal phase half-life in plasma, calculated as [(ln 2)/?z]. t1/2 was only calculated when a reliable estimate for ?z could be obtained.	Blood samples for oral azacitidine PK assessment were collected prior to each dose (pre-dose) and over the 8-hour period following each dose (0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose or similar schedule).
Secondary	Apparent Total Clearance (CL/F) Of CC-486	Apparent volume of distribution, calculated as [(CL/F)/?z].	Blood samples for oral azacitidine PK assessment were collected prior to each dose (pre-dose) and over the 8-hour period following each dose (0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose or similar schedule).
Secondary	Apparent Volume of Distribution (Vz/F) Of CC-486	Apparent volume of distribution, calculated as [(CL/F)/?z].	Blood samples for oral azacitidine PK assessment were collected prior to each dose (pre-dose) and over the 8-hour period following each dose (0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose or similar schedule).